Gf Fund Management Co. Ltd. Biocryst Pharmaceuticals Inc Transaction History
Gf Fund Management Co. Ltd.
- $5.51 Trillion
- Q3 2025
A detailed history of Gf Fund Management Co. Ltd. transactions in Biocryst Pharmaceuticals Inc stock. As of the latest transaction made, Gf Fund Management Co. Ltd. holds 4,516 shares of BCRX stock, worth $31,973. This represents 0.0% of its overall portfolio holdings.
Number of Shares
4,516
Previous 5,303
14.84%
Holding current value
$31,973
Previous $47.5 Million
27.86%
% of portfolio
0.0%
Previous 0.0%
Shares
3 transactions
Others Institutions Holding BCRX
# of Institutions
310Shares Held
200MCall Options Held
640KPut Options Held
507K-
Vanguard Group Inc Valley Forge, PA21.8MShares$154 Million0.0% of portfolio
-
Black Rock Inc. New York, NY20MShares$141 Million0.0% of portfolio
-
Deerfield Management Company, L.P. (Series C) New York, NY12.2MShares$86.2 Million1.72% of portfolio
-
State Street Corp Boston, MA9.81MShares$69.4 Million0.0% of portfolio
-
Kynam Capital Management, LP Princeton, NJ9.39MShares$66.5 Million6.02% of portfolio
About BIOCRYST PHARMACEUTICALS INC
- Ticker BCRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 185,944,992
- Market Cap $1.32B
- Description
- BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat...